Germany · Delayed Price · Currency is EUR Immunic Statistics
Total Valuation
Immunic has a market cap or net worth of EUR 70.26 million. The enterprise value is 40.72 million.
| Market Cap | 70.26M |
| Enterprise Value | 40.72M |
Important Dates
The next estimated earnings date is Thursday, February 26, 2026.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 120.28M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +53.56% |
| Shares Change (QoQ) | +96.55% |
| Owned by Insiders (%) | 1.44% |
| Owned by Institutions (%) | 29.14% |
| Float | 101.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 7.85 |
| P/TBV Ratio | 7.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.46 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.53 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.08.
| Current Ratio | 1.31 |
| Quick Ratio | 1.17 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -398.50% and return on invested capital (ROIC) is -246.99%.
| Return on Equity (ROE) | -398.50% |
| Return on Assets (ROA) | -125.08% |
| Return on Invested Capital (ROIC) | -246.99% |
| Return on Capital Employed (ROCE) | -993.24% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -975,855 |
| Employee Count | 91 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.55% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -47.55% |
| 50-Day Moving Average | 0.69 |
| 200-Day Moving Average | 0.79 |
| Relative Strength Index (RSI) | 44.49 |
| Average Volume (20 Days) | 4,678 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.04 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -89.94M |
| Pretax Income | -87.83M |
| Net Income | -87.83M |
| EBITDA | -89.81M |
| EBIT | -89.94M |
| Earnings Per Share (EPS) | -0.66 |
Balance Sheet
The company has 29.94 million in cash and 675,022 in debt, giving a net cash position of 29.27 million.
| Cash & Cash Equivalents | 29.94M |
| Total Debt | 675,022 |
| Net Cash | 29.27M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 8.95M |
| Book Value Per Share | 0.09 |
| Working Capital | 7.84M |
Cash Flow
In the last 12 months, operating cash flow was -76.27 million and capital expenditures -130,402, giving a free cash flow of -76.40 million.
| Operating Cash Flow | -76.27M |
| Capital Expenditures | -130,402 |
| Free Cash Flow | -76.40M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunic does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -53.56% |
| Shareholder Yield | -53.56% |
| Earnings Yield | -125.01% |
| FCF Yield | -108.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |